Clinical usefulness of FDG-PET for pancreatic cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 13, 2009, Pages 2516-2520

  Mataki, Yuko ^a   Shinchi, Hiroyuki ^a   Kurahara, Hiroshi ^a   Maemura, Kosei ^a   Noma, Hidetoshi ^a   Natsugoe, Shoji ^a   Takao, Sonshin ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

FDG PET; Pancreatic cancer; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE; CANCER CLASSIFICATION; CANCER INVASION; CANCER SURVIVAL; COLON; DRUG ACCUMULATION; DRUG UPTAKE; GALLBLADDER; HUMAN; LIVER; LUNG; LYMPH NODE; MAJOR CLINICAL STUDY; PANCREAS; PANCREAS CANCER; PERITONEUM; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME; VISCERA;

EID: 79959773393     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Maemura K, Takao S, Shinchi H, et al: Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 13:435-441, 2006. (Pubitemid 44480247)
2. Ruf J, Lopez Hänninen E, Oettle H, et al: Detection of recurrent pancreatic cancer comparison of FDG-PET with CT/MRI. Pancreatology 5:266-272, 2005. (Pubitemid 40754748)
3. Bang S, Chung HW, Park SW, et al: The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923-929, 2006. (Pubitemid 44690768)
4. Nakata B, Chung YS, Nishimura S, et al: 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79:695-699, 1997. (Pubitemid 27076335)
5. Higashi T, Tamaki N, Torizuka T, et al: FDG uptake. GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39:1727-1735, 1998. (Pubitemid 28473521)
6. Diederichs CG, Staib L, Glatting G, et al: FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39:1030-1033, 1998.
7. Kobayashi N, Fujita K, Fujisawa T, et al: [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer?]. Gan To Kagaku Ryoho 35(1):65-70, 2008.
8. Higashi T, Saga T, Nakamoto Y, et al: Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - usefulness and limitations in "clinical reality". Ann Nucl Med 17:261-279, 2003.
9. Delbeke D: Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 40:591-603, 1999.
10. Kinkel K, Lu Y, Both M, et al: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224:748-756, 2002. (Pubitemid 34919808)
11. Fröhlich A, Diederichs CG, Staib L, et al: Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40:250-255, 1999. (Pubitemid 29077086)
12. Heinrich S, Goerres GW, Schäfer M, et al: Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235-243, 2005. (Pubitemid 41033440)